Yes. The native eukaryotic folding and glycosylation machinery of barley cells produces proteins with a conformation and activity profile comparable or superior to mammalian-expressed alternatives. Each batch is tested for biological activity using cell-based proliferation assays, and bioactivity data is provided with every lot.

Endotoxins trigger pro-inflammatory responses that interfere with stem cell proliferation, differentiation, and downstream assay accuracy. Conventional bacterial-expression systems introduce endotoxin as a production by-product; post-production cleanup reduces but does not eliminate the risk. ISOkine® proteins are produced in a plant host that does not use bacteria or animal cells, making them endotoxin-free by design, not by filtration. ISOkine® comes in at <0.01 EU/µg.

Yes. ISOkine® proteins are available for both research-scale and larger-scale cell culture applications. ORF Genetics has been producing the ISOkine® line since 2007; the Orfeus barley-seed platform supports scale-up without reformulation or product change. Talk to a scientist about your volume requirements.

Every lot ships with a Certificate of Analysis (CoA), a Safety Data Sheet (SDS), a product datasheet, and a Certificate of Origin. ISOkine® proteins are animal- and serum-free, void of antibiotics, with low pyrogenic activity, making them compatible with defined-condition protocols for pre-clinical and early clinical development. ORF Genetics is ISO 9001:2015 certified and on the road to GMP certification.

The key difference is the production host. ISOkine® proteins are produced in bioengineered barley, not in E. coli or mammalian cell lines. This plant host eliminates animal-derived contamination by design, produces proteins with native eukaryotic folding, and enables a cost structure significantly lower than conventional pricing. The production system has been running for over 18 years, providing consistent quality data across that track record.